Background Rituximab is often used as rescue therapy in interstitial lung disease (ILD)
associated with connective tissue disease (CTD), but has not been studied in clinical trials …

Background Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …

Introduction/objectives To evaluate rituximab (RTX) effectiveness and safety in patients with
interstitial lung disease (ILD) related to connective tissue diseases (CTD). Methods …

Objective. CTD-associated interstitial lung disease (ILD) often fails to respond to
conventional immunomodulatory agents. There is now considerable interest in the use of …

In very severe interstitial lung disease associated with connective tissue disease (CTD-ILD),
progressing despite maximal conventional immunosuppression, there is no effective …

OBJECTIVES Interstitial lung disease (ILD) is a key prognostic factor in connective tissue
disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional …

Objective To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue
therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease (RA …

Background: The American Thoracic Society convened an international, multidisciplinary
panel to develop clinical practice guidelines for the treatment of systemic sclerosis …

Background Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial
pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step …

Background and objective In patients with severe interstitial lung disease (ILD) progressing
despite conventional immunosuppression, rituximab, a B‐lymphocyte depleting monoclonal …